Inflammatory Biomarkers
Revised McDonald criteria allow for diagnosis of multiple sclerosis in atypical cases
WEST PALM BEACH, Fla. — Revisions made in 2024 to the McDonald criteria allowed for the diagnosis of multiple sclerosis in a small cohort of individuals with atypical presentation, according to a speaker at ACTRIMS.
International group revises diagnostic guidance for Alzheimer’s
The International Working Group has updated diagnostic guidelines for Alzheimer’s disease to include individuals with normal cognition who test positive for core biomarkers indicative of disease pathology.
Filgotinib maintains remission, improves quality of life over 4 years in UC
Long-term filgotinib induced and maintained symptomatic remission and improved health-related quality of life in ulcerative colitis, with no new safety signals reported, according to interim analysis of the SELECTION extension study.
Neutrophil-to-lymphocyte ratio may aid diagnosis of infectious, idiopathic orbital disease
The neutrophil-to-lymphocyte ratio appeared to distinguish between acute orbital infectious disease and noninfectious inflammation and may aid in clinical intervention, according to a study in Ophthalmic Plastic and Reconstructive Surgery.
Metagenomic sequencing may be valuable for diagnosing infectious disease
DENVER — Metagenomic next-generation sequencing may be a reliable diagnostic tool to analyze causes of highly contagious meningitis or encephalitis in a clinical setting, according to a speaker.
KT-474 reduces inflammation in patients with hidradenitis suppurativa, atopic dermatitis
Results from a phase 1 study show that KT-474 reduced disease-relevant inflammatory biomarkers in the blood and skin of patients with hidradenitis suppurativa or atopic dermatitis, according to a Kymera Therapeutics press release.
Pitavastatin lowers plaque volume, progression in lower-risk patients with HIV
PHILADELPHIA — Pitavastatin lowered noncalcified plaque volume and reduced risk for plaque progression compared with placebo in patients with HIV at low to moderate risk for CVD, according to new data from the REPRIEVE trial.
Tralokinumab may neutralize IL-13 levels in atopic dermatitis
Interleukin-13 may be the central cytokine in the skin of patients with atopic dermatitis, and by blocking interleukin-13 with targeted therapies it is possible to block many key disease characteristics such as skin barrier deficiency, according to research presented at European Academy of Dermatology and Venereology Congress.